Running With Plandai Biotechnology
Plandai Biotechnology Inc (OTCMKTS:PLPL) has had a year and a half that Investors would love to forget as the stock has continue to lose ground falling from several dollars a share to recent lows near a dime.
PLPL has a long history of big moves making a spectacular run back in early 2015 when pot stocks got hot and ruled the bb’s running from pennies to highs well over $3 a share.
Plandai Biotechnology Inc (OTCMKTS:PLPL) and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaì Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare(TM) extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.
The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.
PLPL products include Phytofare™ Catechin Complex, a water-soluble powder, Ph2™ Topical Catechin Complex, a topical cream that has Phytofare™ nano-entrapped in Pheroid™, Ph2™ Oral Catechin Complex, a gel tab version of Phytofare™ nano-entrapped in Pheroid™, suitable for oral consumption, and Ph2™ Liquid Catechin Complex, an oral version of Phytofare™ nano-entrapped in Pheroid™ in a liquid suspension, suitable for mixing into beverages and liquid medications.
Last year PLPL started two clinical trials. The first includes 35 participants and focuses on the depth of penetration of the company’s Phytofare™ Pheroid™ Catechin Complex to demonstrate that Plandaí’s product can be effectively used in topical creams to deliver Phytofare™ into target tissues. The second clinical trial includes 35 participants, and focuses on the anti-inflammatory properties of Plandaí’sPhytofare™ Pheroid™ Catechin Complex. The company’s goal is to show reduced redness and irritation in a topical application which will allow Phytofare™ to be used in various skin care products.
Plandaì Biotechnology – Uruguay, SA, a wholly owned subsidiary of Plandaì Biotechnology, is currently the only company given authorization to grow cannabis and conduct medical research in Uruguay. Published research indicates that Plandaì’s proprietary extraction process should render the complete cannabinoid complex from the live plant while retaining the acid forms of THC, which are devoid of psychotropic effects. The result should be a highly bioavailable extract that retains all of the potential medical benefits of cannabis without the psychoactive properties. Plandaì intends to establish a pharmaceutical platform in once the initial scientific investigations have been successfully completed.
On August 26 PLPL announced Ultimate Sports Nutrition (USN) is investigating and developing a new line of products for the Australian and New Zealand markets that incorporates Plandaí’s green tea catechin-based Phytofare® ingredient. Under the terms of a previously announced agreement, USN is committed to using Phytofare® catechin complex exclusively in all products manufactured or sold in Europe and South Africa that incorporate green tea.
In an effort to further develop and expand on the existing agreement, the Company and USN agreed to allow USN to explore the use of Phytofare® with other USN contract manufacturers, beginning in Australia and New Zealand, in an attempt to determine whether further expansion of the relationship between the Company and USN was desirable.
Currently trading at a $20 million market valuation PLPL has minimal assets or revenues and a significant debt problem with $15 million in payables (that can lead to massive dilution) PLPL is an exciting Company known as the producer of the highly bioavailable Phytofare® catechin complex.
PLPL has a long history of big moves making a spectacular run back in early 2015 when pot stocks got hot and ruled the bb’s running from pennies to highs well over $3 a share.
Plandai Biotechnology Inc (OTCMKTS:PLPL) and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaì Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare(TM) extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.
The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.
PLPL products include Phytofare™ Catechin Complex, a water-soluble powder, Ph2™ Topical Catechin Complex, a topical cream that has Phytofare™ nano-entrapped in Pheroid™, Ph2™ Oral Catechin Complex, a gel tab version of Phytofare™ nano-entrapped in Pheroid™, suitable for oral consumption, and Ph2™ Liquid Catechin Complex, an oral version of Phytofare™ nano-entrapped in Pheroid™ in a liquid suspension, suitable for mixing into beverages and liquid medications.
Last year PLPL started two clinical trials. The first includes 35 participants and focuses on the depth of penetration of the company’s Phytofare™ Pheroid™ Catechin Complex to demonstrate that Plandaí’s product can be effectively used in topical creams to deliver Phytofare™ into target tissues. The second clinical trial includes 35 participants, and focuses on the anti-inflammatory properties of Plandaí’sPhytofare™ Pheroid™ Catechin Complex. The company’s goal is to show reduced redness and irritation in a topical application which will allow Phytofare™ to be used in various skin care products.
Plandaì Biotechnology – Uruguay, SA, a wholly owned subsidiary of Plandaì Biotechnology, is currently the only company given authorization to grow cannabis and conduct medical research in Uruguay. Published research indicates that Plandaì’s proprietary extraction process should render the complete cannabinoid complex from the live plant while retaining the acid forms of THC, which are devoid of psychotropic effects. The result should be a highly bioavailable extract that retains all of the potential medical benefits of cannabis without the psychoactive properties. Plandaì intends to establish a pharmaceutical platform in once the initial scientific investigations have been successfully completed.
On August 26 PLPL announced Ultimate Sports Nutrition (USN) is investigating and developing a new line of products for the Australian and New Zealand markets that incorporates Plandaí’s green tea catechin-based Phytofare® ingredient. Under the terms of a previously announced agreement, USN is committed to using Phytofare® catechin complex exclusively in all products manufactured or sold in Europe and South Africa that incorporate green tea.
In an effort to further develop and expand on the existing agreement, the Company and USN agreed to allow USN to explore the use of Phytofare® with other USN contract manufacturers, beginning in Australia and New Zealand, in an attempt to determine whether further expansion of the relationship between the Company and USN was desirable.
Currently trading at a $20 million market valuation PLPL has minimal assets or revenues and a significant debt problem with $15 million in payables (that can lead to massive dilution) PLPL is an exciting Company known as the producer of the highly bioavailable Phytofare® catechin complex.
